Search
Hyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[L13338] The action of hyaluronidase was first described in 1936, and named in 1939. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]
Dosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalDosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigational[A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).
Quaternium-15
go.drugbank.com/drugs/DB14198ApprovedQuaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics. … In 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].
Islatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for
Dipyrithione
go.drugbank.com/drugs/DB11327Approved[A32825] Pyrithione derivatives, such as [DB06815] and sodium pyrithione, are widely used as cosmetic preservatives and as anti-dandruff agents in shampoos. … Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available.
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalLinvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma … This mechanism results in the targeted release of cytokines such as IL-2, IL-6, and IFN-gamma, promoting the selective lysis of BCMA-expressing cells and offering a novel immunotherapeutic approach for
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907]
Light green SF yellowish
go.drugbank.com/drugs/DB11183ApprovedAlthough it has been used as a food colorant, it was discontinued from the market due to low popularity which are possibly due to low durability of the dye and increased tendency of the dye to fade. … Light green SF yellowish is also available as sterile strips used as a diagnostic agent when superficial corneal or conjunctival tissue change is suspected.
Cefoperazone
go.drugbank.com/drugs/DB01329ApprovedInvestigationalWithdrawnWhile its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.